Announcements Trials
Browse Landscape

Phase

Phase 2 5Phase 1 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Colorectal Neoplasms 59Pancreatic Neoplasms 33Colonic Neoplasms 31Rectal Neoplasms 30Stomach Neoplasms 22Neoplasm Metastasis 19Carcinoma, Non-Small-Cell Lung 19Neoplasms 16Unspecified Adult Solid Tumor, Protocol Specific 15Esophageal Neoplasms 12Ovarian Neoplasms 8Gallbladder Neoplasms 7Appendiceal Neoplasms 7Melanoma 6Lymphoma, Large B-Cell, Diffuse 6Lung Neoplasms 6Carcinoma, Renal Cell 6Breast Neoplasms 6Bile Duct Neoplasms 6Peritoneal Neoplasms 5Liver Neoplasms 5Gastrointestinal Neoplasms 5Carcinoma, Hepatocellular 5Adenocarcinoma 5Triple Negative Breast Neoplasms 4Recurrence 4Fallopian Tube Neoplasms 4Esophageal Squamous Cell Carcinoma 4Carcinoma, Pancreatic Ductal 4Squamous Cell Carcinoma of Head and Neck 3

Interventions

vorolanib 1spartalizumab 1camrelizumab 1Paclitaxel 1Oxaliplatin 1Everolimus 1Capecitabine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1 × Advanced Gastric Cancer × Oxaliplatin × Clear all
NCT01049620 2020-01-07

RAD001 in Combination With Capecitabine and Oxaliplatin (XELOX) in Patients With Advanced Gastric Cancer: RAD001+XELOX

Asan Medical Center

Phase 1 Completed
40 enrolled
Gastrointestinal

Advanced Gastric Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡